## REMARKS

This response changes the claims of this application. Accordingly, a detailed listing is presented, with appropriately defined status identifiers, for all claims that are or were in the application, irrespective of what claims remain under examination. In particular, claim 1 is amended currently and claim 14 is identified for cancellation. Thus, claims 1 - 13 will be pending, upon entry of the present amendment.

As to the restriction requirement set forth in the Office Action, Applicants elect claims 6-8, 13, and 14 of Group II, drawn to a polypeptide. This election is made with traverse because, Applicants submit, the claims as currently amended relate to a single inventive concept and should be examined together. More specifically, the present claims are not subject to the stated grounds for the alleged lack of unity, namely, that Warren *et al.* (WO/0260942) is anticipatory of claim 1 by virtue of teaching "an isolated DNA sequence that encodes a polypeptide that is 99.5% identical to SEQ ID NO:48."

Accordingly, withdrawal of pending restriction and an early indication of allowability are requested. Also, Examiner Bunner is invited to contact the undersigned directly, should she feel that any point warrants consideration.

Finally, the Commissioner is hereby authorized to charge any additional fees, which may be required regarding this application under 37 CFR §§ 1.16-1.17, and to credit any overpayment to Deposit Account No. 19-0741. Should no proper payment accompany this response, then the Commissioner is authorized to charge the unpaid amount to the same deposit account. If any extension is needed for timely acceptance of submitted papers, Applicants petition for such extension under 37 CFR §1.136 and authorize payment of relevant fees from the deposit account.

Respectfully submitted,

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone:

(202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent Attorney for Applicant Registration No. 29,768